SPIROMICS队列中COPD患者急性加重频率的年度变异性分析
该研究基于SPIROMICS前瞻性队列,分析1105例COPD患者3年随访数据,发现49%患者至少有一次急性加重,但仅7%每年至少一次,2%每年至少两次,41%呈不一致模式;持续加重与基线症状负担、既往加重史、CT小气道异常及IL-15、IL-8浓度相关。
要点
- COPD患者急性加重年际变异大,仅少数每年反复加重。
- 持续加重与基线症状负担、既往加重史及CT小气道异常相关。
- IL-15降低和IL-8升高与持续加重相关,为潜在新型生物标志物。
核心结论
- 尽管急性加重常见,但多数患者加重状态年际变化明显,持续每年≥2次加重者极少。
- 除症状和既往加重史外,CT小气道异常及IL-15、IL-8浓度与持续加重相关。
研究设计与样本
- SPIROMICS队列纵向前瞻性分析,纳入40-80岁COPD患者,2010年11月12日至2015年7月31日入组。
- 2981例入组,1843例COPD,1105例有3年完整前瞻性随访数据。
主要发现
- 1105例中538例(49%)3年内至少一次急性加重,567例(51%)无加重。
- 82例(7%)每年至少一次急性加重,仅23例(2%)每年至少两次。
- 456例(41%)呈不一致模式(有加重年和无加重年并存),其中GOLD 3-4期占256例(56%)。
- 逻辑回归显示持续加重(3年每年≥1次)与更高基线症状负担、既往加重、CT小气道异常证据更多、IL-15浓度更低及IL-8浓度更高相关。
临床怎么用
- 评估COPD加重风险时需考虑年际变异,不能仅凭单一年份加重史分层。
- 基线症状负担、既往加重史、CT小气道异常及IL-15/IL-8或有助于识别持续加重高风险患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Present treatment strategies to stratify exacerbation risk in patients with chronic obstructive pulmonary disease (COPD) rely on a history of two or more events in the previous year. We aimed to understand year to year variability in exacerbations and factors associated with consistent exacerbations over time. METHODS: In this longitudinal, prospective analysis of exacerbations in the Subpopulations and Intermediate Outcome Measures in COPD Study (SPIROMICS) cohort, we analysed patients aged 40-80 years with COPD for whom 3 years of prospective data were available, identified through various means including care at academic and non-academic medical centres, word of mouth, and existing patient registries. Participants were enrolled in the study between Nov 12, 2010, and July 31, 2015. We classified patients according to yearly exacerbation frequency: no exacerbations in any year; one exacerbation in every year during 3 years of follow-up; and those with inconsistent exacerbations (individuals who had both years with exacerbations and years without during the 3 years of follow-up). Participants were characterised by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) spirometric category (1-4) on the basis of post-bronchodilator FEV1. Stepwise logistic regression was used to compare factors associated with one or more acute exacerbations of COPD every year for 3 years versus no exacerbations in the same timeframe. Additionally, a stepwise zero-inflated negative binomial model was used to assess predictors of exacerbation count during follow-up in all patients with available data. Baseline symptom burden was assessed with the COPD assessment test. This trial is registered with ClinicalTrials.gov, number NCT01969344. FINDINGS: 2981 patients were enrolled during the study. 1843 patients had COPD, of which 1105 patients had 3 years of complete, prospective follow-up data. 538 (49%) of 1105 patients had at least one acute exacerbation during the 3 years of follow-up, whereas 567 (51%) had none. 82 (7%) of 1105 patients had at least one acute exacerbation each year, whereas only 23 (2%) had two or more acute exacerbations in each year. An inconsistent pattern (both years with and without acute exacerbations) was common (456 [41%] of the group), particularly among GOLD stages 3 and 4 patients (256 [56%] of 456). In logistic regression, consistent acute exacerbations (≥1 event per year for 3 years) were associated with higher baseline symptom burden, previous exacerbations, greater evidence of small airway abnormality on CT, lower interleukin-15 concentrations, and higher interleukin-8 concentrations, than were no acute exacerbations. INTERPRETATION: Although acute exacerbations are common, the exacerbation status of most individuals varies markedly from year to year. Among patients who had any acute exacerbation over 3 years, very few repeatedly had two or more events per year. In addition to symptoms and history of exacerbations in the year before study enrolment, we identified several novel biomarkers associated with consistent exacerbations, including CT-defined small airway abnormality, and interleukin-15 and interleukin-8 concentrations. FUNDING: National Institutes of Health, and National Heart, Lung, and Blood Institute.
引用
- Han MK, Quibrera PM, Carretta EE, et al. Frequency of exacerbations in patients with chronic obstructive pulmonary disease: an analysis of the SPIROMICS cohort. Lancet Respir Med. 2017. PMID: 28668356. doi:10.1016/S2213-2600(17)30207-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。